Clinical Trial Detail

NCT ID NCT03531827
Title Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

prostate cancer


CRLX101 + Enzalutamide

Age Groups:

No variant requirements are available.